Search results for "recombinant protein"

showing 10 items of 707 documents

Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure.

2003

The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure undergoing periodic hemodialysis. The goal is to carry out an individualised prediction of the erythropoietin dosage to be administered. It is justified because of the high cost of this medication, its secondary effects and the phenomenon of potential resistance which some individuals suffer. One hundred and ten patients were included in this study and several factors were collected in order to develop the neural models. Since the results obtained were excellent, an easy-to-use decision-aid computer application was implemented.

medicine.medical_specialtymedicine.diagnostic_testAnemiaSecondary anemiabusiness.industrymedicine.medical_treatmentHealth InformaticsAnemiamedicine.diseaseRecombinant ProteinsComputer Science ApplicationsTherapeutic drug monitoringErythropoietinmedicineQuality of LifeChronic renal failureHumansKidney Failure ChronicIn patientHemodialysisNeural Networks ComputerIntensive care medicinebusinessErythropoietinmedicine.drugComputers in biology and medicine
researchProduct

Possible Pathogenetic Relevance of Interleukin-1beta in "Destructive" Organ-specific Autoimmune Disease (Hashimoto's Thyroiditis)

1999

Thyroid follicular cells (TFC) abundantly express a variety of immunologically relevant surface molecules in Hashimoto's thyroiditis (HT), for example, MHC antigens and adhesion molecules such as ICAM-1. Cytokines produced by infiltrating type 1 helper and cytotoxic T cells are importantly involved in de novo expression or up-regulation of such molecules. We recently demonstrated that TFC from HT patients almost invariably bear on their surface two additive functional molecules: Fas/Apo1/CD95, an important participant in apoptosis, and B7.1, a member of a family of "co-stimulatory" molecules that are crucial for efficient antigen presentation. To date, 12 out of 14 surgical HT thyroid speci…

medicine.medical_specialtymedicine.medical_treatmentAntigen presentationThyroid Glandmedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyFas ligandAutoimmunityHistory and Philosophy of ScienceInternal medicinemedicineHumansCytotoxic T cellfas ReceptorChemistryGeneral NeuroscienceThyroiditis AutoimmuneInterleukinFas receptorMolecular biologyGraves DiseaseRecombinant ProteinsCytokineEndocrinologyApoptosisB7-1 AntigenCytokinesInterleukin-1Annals of the New York Academy of Sciences
researchProduct

Effect of Soluble Interleukin-6 Receptor on Interleukin-6 Synthesis in Human Skin Fibroblasts

1996

Abstract In this study the ability of soluble interleukin-6 receptor (sIL-6R) to stimulate interleukin-6 (IL-6) synthesis in human fibroblasts is described. It was found that sIL-6R, in combination with endogenous or exogenous IL-6, markedly upregulated IL-6 synthesis. These data suggest that increased IL-6 production after stimulation by either interleukin-1 or tumor necrosis factor-α would result in complex formation with sIL-6R, rapid uptake, and further synthesis of this cytokine. Furthermore, it would explain the decrease in sIL-6R plasma levels observed in patients suffering from sepsis.

medicine.medical_specialtymedicine.medical_treatmentBiophysicsGene ExpressionHuman skinStimulationEndogenyBiochemistryDownregulation and upregulationAntigens CDInternal medicinemedicineHumansInterleukin 6ReceptorMolecular BiologyCells CulturedSkinbiologyInterleukin-6Receptors InterleukinCell BiologyFibroblastsReceptors Interleukin-6Recombinant ProteinsKineticsCytokineEndocrinologybiology.proteinTumor necrosis factor alphaBiochemical and Biophysical Research Communications
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Ultrasound-induced blood clot dissolution without a thrombolytic drug is more effective with lower frequencies.

2004

<i>Background and Purpose:</i> Therapeutic ultrasound as stand-alone therapy or in combination with rt-PA has proven to be an effective measure for recanalisation of acute vessel occlusion in different in vitro and in vivo studies. Uncertainty still exists concerning the optimal frequency and intensity with regard to the thrombolytic efficacy of ultrasound. The purpose of this study was a direct comparison of different ultrasound frequencies, when otherwise using identical measurement settings and parameters. <i>Methods:</i> Ultrasound-induced dissolution of fresh human blood clots was studied in a flow system using low-frequency continuous wave ultrasound of 20, 40 …

medicine.medical_specialtymedicine.medical_treatmentVessel occlusionThrombolytic drugInternal medicinemedicineHumansThrombolytic TherapyUltrasonicsStrokeBlood CoagulationUltrasonographyTherapeutic ultrasoundbusiness.industryUltrasoundAnticoagulantsThrombolysisFrequency dependencemedicine.diseaseRecombinant ProteinsSurgeryBloodNeurologyCalibrationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular diseases (Basel, Switzerland)
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct

Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo.

2011

Identification of physiologically relevant substrates is still the most challenging part in protease research for understanding the biological activity of these enzymes. The zinc-dependent metalloprotease meprin β is known to be expressed in many tissues with functions in health and disease. Here, we demonstrate unique interactions between meprin β and the amyloid precursor protein (APP). Although APP is intensively studied as a ubiquitously expressed cell surface protein, which is involved in Alzheimer disease, its precise physiological role and relevance remain elusive. Based on a novel proteomics technique termed terminal amine isotopic labeling of substrates (TAILS), APP was identified …

medicine.medical_treatmentBiologyProteomicsBiochemistryPolymerase Chain ReactionCell LineSubstrate Specificity03 medical and health sciencesAmyloid beta-Protein PrecursorMice0302 clinical medicinemental disordersAmyloid precursor proteinmedicineAnimalsHumansProtein IsoformsMolecular Biology030304 developmental biologyDNA Primerschemistry.chemical_classification0303 health sciencesMetalloproteinaseProteaseBase SequenceNeurodegenerationTioproninBrainCell BiologyTerminal amine isotopic labeling of substratesmedicine.diseaseIn vitroRecombinant Proteins3. Good healthMice Inbred C57BLEnzymechemistryBiochemistryProtein Synthesis and Degradationbiology.protein030217 neurology & neurosurgeryThe Journal of biological chemistry
researchProduct

Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF

1989

Abstract We assessed the capacity of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and multilineage (Multi)-CSF to induce release of granulocyte-CSF (G-CSF) by highly purified peripheral blood monocyte (Mo) preparations. Our results reveal that GM-CSF and Multi-CSF, either alone or in a synergistic concert, activate Mo to transcribe G-CSF messenger (m) RNA and release biologically active G- CSF protein into their culture supernatants. G-CSF had no regulatory effect on Mo expression of cytoplasmic G-CSF mRNA levels and G-CSF protein secretion by itself. These differential actions of CSFs provide further insight into self-regulatory mechanisms within the growth f…

medicine.medical_treatmentImmunologyGranulocyteBiologyBiochemistryMonocyteslaw.inventionColony-Stimulating FactorslawmedicineHumansRNA MessengerGrowth SubstancesCells CulturedCSF albuminCell-Free SystemGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorRNABiological activityCell BiologyHematologyMolecular biologyRecombinant ProteinsDrug CombinationsGranulocyte macrophage colony-stimulating factorSecretory proteinmedicine.anatomical_structureImmunologyRecombinant DNAGranulocytesmedicine.drugBlood
researchProduct

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

medicine.medical_treatmentImmunologyIntercellular Adhesion Molecule-1BiologyGeneral Biochemistry Genetics and Molecular BiologyTh2 CellsRheumatologyOsteoarthritisCell AdhesionmedicineHumansImmunology and AllergyInterferon gammaCell adhesionCells CulturedInterleukin-13Interleukin-6Cell adhesion moleculeSynovial MembraneLymphokineReceptors InterleukinFibroblastsTh1 CellsIntercellular Adhesion Molecule-1Molecular biologyRecombinant ProteinsReceptors Interleukin-4Cytokinemedicine.anatomical_structureImmunologyCytokinesTumor necrosis factor alphaInterleukin-4Synovial membraneResearch Articlemedicine.drug
researchProduct

Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice.

1992

Abstract Cytochrome P450 IID6 is a drug metabolizing enzyme and the major target antigen in LKM-1 antibody positive chronic active hepatitis. The histological hallmark of chronic active hepatitis is a lymphocytic infiltrate in the liver. It is unknown whether and how cytokines produced and secreted by these tissue infiltrating mononuclear cells regulate the cellular expression of cytochrome P450 IID6. To study the effect of interleukin 1, tumor necrosis factor and interleukin 6 on the hepatocellular RNA expression of cytochrome P450 IID, we injected each of the cytokines in C3H HeJ mice. We found a time-dependent suppression of the cytochrome in the liver. Six hours after the intraperitonea…

medicine.medical_treatmentIntraperitoneal injectionBiophysicsBiochemistryMixed Function OxygenasesMiceCytochrome P-450 Enzyme SystemmedicineEscherichia coliAnimalsHumansInterleukin 6Molecular BiologyHepatitisMice Inbred C3HbiologyInterleukin-6Tumor Necrosis Factor-alphaCytochrome P450InterleukinCell Biologymedicine.diseaseBlotting NorthernRecombinant ProteinsEndotoxinsCytokineCytochrome P-450 CYP2D6LiverImmunologybiology.proteinRNATumor necrosis factor alphaFemaleAntibodyInterleukin-1Biochemical and biophysical research communications
researchProduct